The landscape of global pharmaceutical innovation is undergoing a seismic shift, and Washington is moving to intervene. A bipartisan proposal introduced on June 2, 2026, seeks to add biotechnology to the purview of the "COINS" Act (Countering Oversight and Intelligence Network Security), a move that would subject licensing and partnership deals between U.S. pharmaceutical giants and China-based firms to unprecedented levels of federal scrutiny.
This legislative effort, spearheaded by Representative John Moolenaar and Representative Debbie Dingell, marks a significant escalation in the ongoing tension between American national security interests and the increasingly intertwined global drug development pipeline. As U.S. companies double down on cross-border collaborations to lower costs and tap into China’s booming research ecosystem, lawmakers are raising alarms that these agreements may be inadvertently hollowing out American research infrastructure and surrendering critical technological advantages.
The Core Conflict: Security vs. Innovation
The central tension driving this legislation is a fundamental disagreement over whether the rapid ascent of China’s biotechnology sector is a boon for global health or a strategic threat to the United States.
Proponents of the legislation argue that the current trajectory of "Big Pharma" is unsustainable. By licensing drug candidates from Chinese labs, U.S. corporations are not merely outsourcing production; they are, according to Moolenaar, "handing Chinese companies a chokehold" over the future of the American economy. The fear is that the transfer of "technological know-how" and the reliance on Chinese-developed assets could leave the U.S. vulnerable, creating a dependency that mirrors the supply chain crises seen in other industries like semiconductors or rare earth minerals.
Conversely, industry veterans and venture capitalists argue that the bill is a reactionary, isolationist policy that risks isolating the U.S. from the global scientific community. They contend that medicine is a collaborative, iterative science that thrives on the cross-pollination of global ideas—a reality that restrictive legislation may permanently damage.
Chronology of a Growing Divide
The path to this legislative showdown has been marked by a decade of rapid expansion in Chinese biotechnology capabilities and an equally rapid cooling of geopolitical relations.
- 2020: Cross-border licensing deals between U.S. and Chinese firms were relatively modest, totaling less than $5 billion. At the time, the Chinese biotech sector was viewed by many Western investors as a promising, low-cost emerging market for clinical trial execution.
- 2024: Concerns regarding intellectual property theft and national security began to dominate the dialogue on Capitol Hill. A bipartisan commission formally recommended that Congress investigate the risks posed by Chinese biotech, suggesting that outbound investment rules were necessary to protect U.S. interests.
- 2025: The U.S. Congress recorded a historic low in legislative output, yet the rhetoric surrounding "de-risking" the Chinese economy intensified. During this period, major U.S. drugmakers began pursuing high-value, long-term partnerships with Chinese firms, sensing that the window for easy cross-border deals might be closing.
- 2026 (June): The formal introduction of the proposal to amend the COINS Act signals the end of the "wait-and-see" approach. The move followed two massive, high-profile deals: Bristol Myers Squibb’s $15.2 billion alliance with Hengrui Pharma and Pfizer’s $10 billion partnership with Innovent Biologics.
Supporting Data: The Scale of the Shift
The sheer volume of capital flowing into these partnerships underscores why lawmakers are so concerned. Licensing transactions between U.S. and Chinese firms exploded from under $5 billion in 2020 to a staggering $136 billion in 2025.
This surge is not merely a reflection of increased spending; it is an indicator of where the next generation of medicines is being birthed. China’s regulatory environment has become increasingly flexible, and its lower costs have made it a preferred venue for early-stage oncology and immunology research. For American pharmaceutical firms, the math is simple: partnering with an established, high-performing Chinese lab is often faster and cheaper than building that capacity in the United States, where labor and R&D costs remain among the highest in the world.
However, critics of this trend point to the "hollowing out" effect. If the core innovation occurs in Shanghai or Suzhou, the long-term domestic capacity for manufacturing and high-level R&D in the United States could atrophy, creating a structural reliance on foreign entities for life-saving therapeutics.
Official Responses and Perspectives
The political response has been bifurcated between national security hawks and those who view the move as a threat to patient outcomes.
The Case for Regulation:
Representative Moolenaar’s position is clear: the current trend of "dangerous deals" threatens the future of American pharmaceutical independence. The goal of the proposed COINS Act amendment is to impose a "regulatory filter" on these deals, ensuring that American investment and technical expertise do not inadvertently strengthen the state-sponsored research sectors of a primary geopolitical rival.
The Industry Pushback:
Bruce Booth, a partner at Atlas Venture, has emerged as a leading voice against the legislation. In his analysis, biotechnology is fundamentally different from the "tech-heavy, secretive" industries usually targeted by national security legislation. He argues that the global scientific community is built on a tradition of shared knowledge. By forcing a retreat from these partnerships, the U.S. risks creating a "balkanized" science landscape.
Booth draws a historical parallel to the rise of Takeda Pharmaceutical. In 1990, the United States viewed Japan’s pharmaceutical expansion with similar fear. Yet, Takeda evolved into a global powerhouse that now serves as a major employer in the U.S., specifically in the biotech hub of Cambridge, Massachusetts. Booth suggests that Chinese firms could follow a similar trajectory—becoming global citizens rather than instruments of the state—if given the opportunity to operate within a competitive, open-market framework.
Implications: A High-Stakes Legislative Battle
The road to passing this legislation is fraught with difficulty. The 2025 Congress set a record for legislative inactivity, and with the November 2026 elections approaching, the political appetite for complex, potentially controversial trade and regulatory legislation is thin.
To succeed, proponents of the amendment will likely need to attach it to a larger, must-pass spending or appropriations package. Even then, the bill faces significant opposition from the pharmaceutical lobby and venture capital firms, who argue that the legislation is misguided.
Potential Consequences of Passage:
- Chilling Effect on Innovation: If licensing deals become subject to intense federal oversight, the speed of drug development could decrease, as companies become hesitant to engage in cross-border partnerships for fear of being blocked or audited.
- Increased Costs: If firms are forced to repatriate R&D or move to more expensive jurisdictions to avoid the "China risk," the costs of drug development will likely rise, potentially leading to higher drug prices for American consumers.
- Geopolitical Retaliation: The Chinese government is unlikely to accept these restrictions quietly. Potential retaliatory measures could include restricted access to China’s patient population for clinical trials or export controls on active pharmaceutical ingredients (APIs), which are already vital to the U.S. drug supply chain.
The Road Ahead
As the debate moves forward, the fundamental question remains: can the United States protect its national security interests without stifling the very global collaboration that makes modern medicine possible?
The advocates of the bill insist that the "opportunity" described by the venture capital community is a facade for long-term strategic vulnerability. Conversely, the skeptics maintain that in an era of globalized science, isolation is a recipe for obsolescence. The outcome of this legislative effort will not only define the future of U.S.-China relations in the pharmaceutical sector but will also likely set the tone for how the U.S. approaches "strategic competition" in high-tech industries for decades to come.
For now, the pharmaceutical industry—and the patients who rely on its innovations—remain in a state of uncertainty, waiting to see if Washington will prioritize the security of the supply chain or the efficiency of global innovation.
About the Author
